December 8, 2021
Life Sciences
  • Pfizer Inc.-BioNTech SE announced that a third dose of their COVID-19 vaccine neutralized the omicron variant and raised antibodies 25-fold in initial lab studies. While the companies said the results offer reassurance that the current formulations will protect against the variant, they are still working on an omicron-specific version of the vaccine, which they plan to have ready by March. (Articles here, here, here, and here)